Log in to save to my catalogue

The clinically approved antiviral drug sofosbuvir inhibits Zika virus replication

The clinically approved antiviral drug sofosbuvir inhibits Zika virus replication

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5241873

The clinically approved antiviral drug sofosbuvir inhibits Zika virus replication

Publication information

Publisher

London: Nature Publishing Group UK

More information

Scope and Contents

Contents

Zika virus (ZIKV) is a member of the
Flaviviridae
family, along with other agents of clinical significance such as dengue (DENV) and hepatitis C (HCV) viruses. Since ZIKV causes neurological disorders during fetal development and in adulthood, antiviral drugs are necessary. Sofosbuvir is clinically approved for use against HCV and targets the...

Alternative Titles

Full title

The clinically approved antiviral drug sofosbuvir inhibits Zika virus replication

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5241873

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5241873

Other Identifiers

ISSN

2045-2322

E-ISSN

2045-2322

DOI

10.1038/srep40920

How to access this item